ARTICLE | Company News
Karo Bio, Aventis deal
October 30, 2000 8:00 AM UTC
KARO will provide AVE access to its BioKey high throughput screening assays for use with AVE's genomics-derived infectious disease targets. KARO said it could receive more than $32 million in the deal...